Homocitrullinated Peptides Induce Pro-Inflammatory T Cell Activation in a Humanized Mouse Model of Rheumatoid Arthritis

Overview

This study investigates the immune responses to homocitrullinated peptides (HomoCitP) in a humanized mouse model of rheumatoid arthritis (RA). It demonstrates that CD4+ T cells can proliferate and exhibit pro-inflammatory characteristics in response to HomoCitP.

Background

Rheumatoid arthritis (RA) is characterized by chronic inflammation and joint damage, with autoantibodies targeting modified proteins playing a key role in its pathogenesis. Homocitrullination, a posttranslational modification, has been linked to severe RA phenotypes.

Data Highlights

No numerical data or trial data were provided in the source material.

Key Findings

• CD4+ T cells from RA patients can proliferate in response to HomoCitP.
• Homocitrullinated proteins are associated with the production of specific autoantibodies in RA.
• The study utilized a humanized DR4-transgenic mouse model to investigate immune responses.
• Elevated levels of Th1 and Th17 cells are observed in RA patients.
• CD8+ T cells activated by citrullinated antigens may contribute to RA pathogenesis.

Clinical Implications

Understanding these immune mechanisms could inform the development of more effective treatments.

Conclusion

This study enhances the understanding of the immune response to homocitrullinated peptides in RA.

Related Resources & Content

1. Choudhury et al., Frontiers in Immunology, 2023 -- Homocitrullinated Peptides Induce Pro-Inflammatory T Cell Activation in a Humanized Mouse Model of Rheumatoid Arthritis
2. the medicine maker — CAR T Cells Target TNF in Mouse Model of Rheumatoid Arthritis
3. Frontiers in Immunology — Pharmacological intervention of the HMGB1-pCTS-L axis to ameliorate inflammatory diseases
4. Frontiers in Immunology — Ligature-induced periodontitis in mice potentially accelerates CD4+ T-cell senescence and exacerbates rheumatoid arthritis
5. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
6. Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study
7. Autoantibodies as predictors of progression to rheumatoid arthritis: a systematic review and meta-analysis | RMD Open